Overview

A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis

Status:
Recruiting

Trial end date:
2024-11-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate how a human body processes ALE.F02 (pharmacokinetics profile) in patients with impaired liver function.

Phase:

Phase 1

Details

Lead Sponsor:

Alentis Therapeutics AG